BioSpace News Archive

CYduct Diagnostics, Inc. today provides a corporate update and letter from President, Dominick Gatto.

Schrödinger, Inc. today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that the first patient has been dosed in its Phase 1 clinical trial of BBP-671, an investigational oral therapy being developed for the potential treatment of conditions caused by coenzyme A (CoA) deficiencies.

Orchard Software and CDR Laboratories have partnered to rapidly implement monkeypox testing.

CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the second quarter and first half of 2022 and provided a business update.

Innovative Cellular Therapeutics, Inc. today announced that the first patient has been enrolled in its Phase I trial of GCC19CART for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC).

Spectral Medical Inc. today announced that following a review of Spectral’s supplemental information to its Investigational Device Exemption (IDE) application, the United States Food and Drug Administration (FDA) has approved the addition of up to ten new clinical trial sites to the Company’s pivotal Tigris trial.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the TakeAim Lymphoma Phase 1/2 study of emavusertib after reviewing the comprehensive data package submitted by Curis.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced that t:slim X2 insulin pump users have delivered more than 1 million insulin boluses using the t:connect app feature on their personal mobile device in the first month following its commercial release.

Arcturus Therapeutics Holdings Inc. today announced updated data from its ongoing ARCT-154 booster clinical trial.